IMR Press / EJGO / Volume 2 / Issue 3 / pii/1981018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

The treatment of 48 patients affected by ovarian carcinoma at stages ІІІ and IV F.I.G.O.

Show Less
1 Department of Obstetrics and Gynaecology, The “Sacro Cuore” Catholic University, Rome (Italy)
Eur. J. Gynaecol. Oncol. 1981, 2(3), 89–97;
Published: 10 October 1981

The Authors analyzed the treatment of 28 patients in stage III (FIGO) and 20 patients in stage IV affected by epithelial ovarian cancer. In these cases, surgery was based on the criterion of cytoreduction and, where possible, maximum radicality. Within a month from surgery, all patients underwent a program of combined chemotherapy (VCR+ 5 FU+CTX) envisaging successive cycles, every four weeks. Minimal side effects were generally observed. 13/28 (46.4%) responses were recorded in stage III and 4/14 (28.6%) in stage IV. The highest percentage of responses, 80%, was obtained in patients with a residual tumor <2 cm, all belonging to stage III. Stage III and stage IV patients with a residual tumor >2 cm responded in 45% and 33% of the cases respectively. Patients who underwent explorative laparotomy showed negligible responses. There was a statistically significant difference survival between stage III and stage IV patients (p < 0.001), among patients with a similar residual tumor >2 cm, but in different stages (p < 0.05), and among stage III patients who responded or not to chemotherapy (p < 0.001).

Ovarian carcinoma
Back to top